#### **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2023

### Biora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation)

001-39334 (Commission File Number)

27-3950390 (IRS Employer Identification No.)

4330 La Jolla Village Drive, Suite 300 San Diego, California (Address of Principal Executive Offices)

92122 (Zip Code)

	Registrant's Telephone Number, Including Area Code: (833) 727-2841							
	(Forme	${f N}/{f A}$ er Name or Former Address, if Changed	Since Last Report)					
Check the a	appropriate box below if the Form 8-K filing is intended to	simultaneously satisfy the fili	ng obligation of the registrant under any of the following provisions:					
	Written communications pursuant to Rule 425 under the	Securities Act (17 CFR 230.42	25)					
	Soliciting material pursuant to Rule 14a-12 under the Exc	change Act (17 CFR 240.14a-	12)					
	Pre-commencement communications pursuant to Rule 14	4d-2(b) under the Exchange Ad	et (17 CFR 240.14d-2(b))					
	Pre-commencement communications pursuant to Rule 13	Be-4(c) under the Exchange Ac	t (17 CFR 240.13e-4(c))					
	Securities registered pursuant to Section 12(b) of the Act:							
		Trading						
	Title of each class	Symbol(s)	Name of each exchange on which registered					
	Common Stock, par value \$0.001 per share	BIOR	The Nasdaq Global Market					
Indicate by	check mark whether the registrant is an emerging growth	company as defined in Rule 40	5 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of					
the Securiti	es Exchange Act of 1934 (§ 240.12b-2 of this chapter).							

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 2.02 Results of Operations and Financial Condition.

On March 30, 2023, Biora Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022 and an updated corporate presentation. The press release and corporate presentation are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K.

As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 and 99.2 incorporated herein shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 and 99.2 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

#### Item 9.01 Financial Statements and Exhibits.

#### (d) Exhibits.

- 99.1 Press release, dated March 30, 2023
- 99.2 <u>Corporate presentation, dated March 30, 2023</u>
- 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

#### SIGNATURES

By:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Biora Therapeutics, Inc.

Date: March 30, 2023

/s/ Aditya P. Mohanty

Aditya P. Mohanty Chief Executive Officer



#### Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

Biora initiating preclinical testing with pharma collaborator's molecule following recent data exceeding the company's target bioavailability levels for systemic therapeutics platform

No adverse events indicated in 14-day tox study for targeted therapeutics program

Announcing new brand names for Biora's therapeutics platforms:; the NaviCap™ targeted oral delivery platform and the BioJet™ systemic oral delivery platform

Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, March 30, 2023 – Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.

Today, the company launched new brand names for its two therapeutics platforms. Its targeted therapeutics platform, previously called the Drug Delivery System (DDS), will now be known as the NaviCap™ targeted oral delivery platform. The NaviCap capsule uses autolocation technology to navigate through the GI tract and deliver drug to a targeted location.

Biora's systemic therapeutics platform, previously called the Oral Biotherapeutic Delivery System (OBDS), is now the BioJet™ systemic oral delivery platform. The BioJet device uses liquid jet injection to deliver biotherapeutics into the small intestine for uptake into systemic circulation. Biora is also taking this opportunity to update its program numbers, replacing PGN with BT, for Biora Therapeutics. A guide to the new platform names and program numbers is available in the Investor Q&A on Biora's website.

Biora recently completed execution of its 14-day toxicology study for its BT-600 program (formerly PGN-600). All planned doses were administered, and the company observed no adverse events or safety signals. The company is completing data analysis and reporting for the study, including analysis of device performance data for the over 600 devices administered during the study.

Biora also recently shared topline results from preclinical studies with two drugs using its BioJet systemic oral delivery platform, in which it achieved more than double its target bioavailability of 15% using an endoscopically placed and activated next-gen device. The company observed an average bioavailability of 37% with semaglutide, a GLP-1 receptor agonist, and an average bioavailability of 51% with adalimumab, a monoclonal antibody. These results significantly exceeded the 15% bioavailability target set by Biora and its pharma collaborators for progression of further development and testing using the platform.

"We are extremely pleased with our recent progress in development of our next-generation BioJet systemic delivery device. The excellent bioavailability results that we observed have enabled us to move forward with preclinical studies with one of our collaborator's molecules, and we are on track for our goal to progress our other collaborations and potential partnerships this year," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "For the NaviCap targeted delivery platform, we achieved an important milestone with the administration of over 600 devices during our 14-day toxicology study for BT-600, which is far more devices than we would expect to administer as part of a phase 1 study. We have some additional work to do to analyze the device performance as part of this animal study, and we look forward to sharing that data with the FDA as we move toward filing our IND for BT-600 later this year," continued Adi Mohanty.

#### Fourth Quarter and Full Year 2022 and Other Recent Corporate Highlights

- Launched new brands to support the company's two therapeutics platforms: the NaviCap targeted oral delivery platform and the BioJet systemic oral delivery platform.
- Announced topline preclinical results with two drugs using the BioJet systemic oral delivery platform, achieving 37% average bioavailability for a GLP-1 receptor agonist and 51% average bioavailability for a variant of adalimumab.
- Preparing to initiate preclinical studies with pharma collaborator's molecule based on the compelling bioavailability data generated recently.
- Presented detailed results from a device function study of the NaviCap platform at the Crohn's & Colitis Congress, demonstrating minimal effect of food upon device performance in healthy patients.
- Completed execution of a 14-day toxicology study for the BT-600 program with initial results indicating no adverse events or safety signals; device performance analysis is ongoing.
- Completed out-license of the Preecludia<sup>™</sup> rule-out test for preeclampsia for commercial development.
- Raised \$12.9 million in gross proceeds during the first quarter through the company's ATM program.

#### Fourth Quarter and Full-Year 2022 Financial Results

#### Comparison of Three Months Ended December 31, 2022 and September 30, 2022

Operating expenses were \$13.8 million for the three months ended December 31, 2022, compared to \$14.0 million for the three months ended September 30, 2022.

Net loss was \$13.7 million and net loss per share was \$1.64 for the three months ended December 31, 2022, compared to net loss of \$5.1 million and net loss per share of \$0.68 for the three months ended September 30, 2022.

Net loss from discontinued operations was \$0.3 million and net loss per share was \$0.03 for the three months ended December 31, 2022, compared to net gain from discontinued operations of \$9.8 million and net gain per share of \$1.31 for the three months ended September 30, 2022.

#### Comparison of Three Months Ended December 31, 2022 and 2021

Operating expenses were \$13.8 million for the three months ended December 31, 2022, compared to \$20.6 million for the three months ended December 31, 2021.

Net loss was \$13.7 million and net loss per share was \$1.64 for the three months ended December 31, 2022, compared to net loss of \$92.9 million and net loss per share of \$13.98 for the three months ended December 31, 2021.

Net loss from discontinued operations was \$0.3 million and net loss per share was \$0.03 for the three months ended December 31, 2022, compared to net loss from discontinued operations of \$10.1 million and net loss per share of \$1.52 for the three months ended December 31, 2021.

#### Comparison of Full Year Ended December 31, 2022 and 2021

The company generated \$12.2 million in revenues for the year ended December 31, 2022, out of which \$11.8 million came from discontinued operations, primarily due to a partial reversal of prior period accruals. The company generated \$60.6 million in revenues for the year ended December 31, 2021, out of which \$59.4 million came from discontinued operations. Operating expenses were \$62.1 million for the year ended December 31, 2022, compared to \$119.1 million for the year ended December 31, 2021.

Net loss was \$38.2 million and net loss per share was \$5.00 for the year ended December 31, 2022, compared to net loss of \$247.4 million and net loss per share of \$64.33 for the year ended December 31, 2021.

Net gain from discontinued operations was \$10.7 million and net gain per share was \$1.40 for the year ended December 31, 2022, compared to net loss from discontinued operations of \$68.9 million and net loss per share of \$17.91 for the year ended December 31, 2021.

#### Webcast and Conference Call Information

Biora Therapeutics will host a webcast and conference call to discuss the fourth quarter and full year 2022 financial results and answer investment community questions today, Thursday, March 30, 2023 at 4:30 PM Eastern time / 1:30 PM Pacific time.

The live call may be accessed by dialing 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and entering the conference code: 10021548. A live webcast will be available via the Investors section of the company website, with a replay available online for 60 days following the call

#### **About Biora Therapeutics**

Biora Therapeutics is the biotech company that is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients' lives. Biora envisions a world where patients have access to needle-free drug delivery and better therapeutic outcomes.

For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter.

#### Safe Harbor Statement or Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning future expectations of our research and development efforts and clinical trials and programs, the safety and efficacy profiles of our product candidates, our goals and plans regarding our IP portfolio and legacy assets and potential addressable market size, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of precision medicine and develop our drug-device combinations, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding future revenue generating opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact Chuck Padala Managing Director, LifeSci Advisors IR@bioratherapeutics.com (646) 627-8390

Media Contact media@bioratherapeutics.com

# Biora Therapeutics, Inc. Condensed Consolidated Statements of Operations (Unaudited)

(In thousands, except share and per share amounts)

		Three Months Ended				
	De	December 31, 2022		September 30, 2022		
Revenues	\$	14	\$	80		
Operating expenses:						
Research and development		5,767		5,820		
Selling, general and administrative		8,023		8,147		
Total operating expenses		13,790		13,967		
Loss from operations		(13,776)		(13,887)		
Interest expense, net		(2,685)		(2,773)		
Gain on warrant liabilities		5,458		2,044		
Other expense, net		(2,207)		(100)		
Loss before income taxes		(13,210)		(14,716)		
Income tax expense		259		158		
Loss from continuing operations		(13,469)		(14,874)		
(Loss) gain from discontinued operations		(253)		9,760		
Net loss	\$	(13,722)	\$	(5,114)		
Net loss per share from continuing operations, basic and diluted	\$	(1.61)	\$	(1.99)		
Net (loss) gain per share from discontinued operations, basic and diluted	\$	(0.03)	\$	1.31		
Net loss per share, basic and diluted	\$	(1.64)	\$	(0.68)		
Weighted average shares outstanding, basic and diluted		8,349,844		7,478,149		

# Biora Therapeutics, Inc. Condensed Consolidated Statements of Operations (Unaudited)

(In thousands, except share and per share amounts)

		Three Months Ended December 31,			Year Ended December 31,			
		2022		2021		2022		2021
Revenues	\$	14		435	\$	305	\$	1,247
Operating expenses:	Ψ			400	Ψ	000	Ψ	±,⊆→≀
Research and development		5,767		8,485		24,049		45,785
Selling, general and administrative		8,023		12,109		38,037		73,299
Total operating expenses		13,790		20,594		62,086		119,084
Loss from operations		(13,776)		(20,159)	-	(61,781)	-	(117,837)
Interest expense, net		(2,685)		(2,186)		(10,990)		(12,636)
Gain (loss) on warrant liabilities		5,458		(48,339)		20,904		(54,157)
Other (expense) income, net		(2,207)		(12,222)		2,617		5,990
Loss before income taxes		(13,210)	-	(82,906)		(49,250)		(178,640)
Income tax expense (benefit)		259		(119)		(420)		(119)
Loss from continuing operations		(13,469)	-	(82,787)		(48,830)		(178,521)
(Loss) gain from discontinued operations		(253)		(10,087)		10,673		(68,891)
Net loss		(13,722)		(92,874)		(38,157)		(247,412)
Net loss per share from continuing operations, basic and diluted	\$	(1.61)	\$	(12.46)	\$	(6.40)	\$	(46.42)
Net (loss) gain per share from discontinued operations, basic and diluted	\$	(0.03)	\$	(1.52)	\$	1.40	\$	(17.91)
Net loss per share, basic and diluted	\$	(1.64)	\$	(13.98)	\$	(5.00)	\$	(64.33)
Weighted average shares outstanding, basic and diluted		8,349,844		6,642,888		7,635,107		3,846,187

# Biora Therapeutics, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands)

		December 31,			
		2022		2021	
Assets					
Current assets:					
Cash and cash equivalents	\$	30,486	\$	88,397	
Accounts receivable, net	•		Ψ	653	
Income tax receivable		828		_	
Prepaid expenses and other current assets		4,199		7,232	
Current assets of disposal group held for sale		2,603		2,493	
Total current assets		38,116		98,775	
Property and equipment, net		1,654		3,666	
Right-of-use assets		1,482		_	
Other assets		6,201		326	
Goodwill		6,072		6,072	
Total assets	\$	53,525	\$	108,839	
Liabilities and Stockholders' Deficit					
Current liabilities:					
Accounts payable	\$	3,606	\$	8,709	
Accrued expenses and other current liabilities		16,161		34,157	
Warrant liabilities		3,538		18,731	
Current portion of capital lease obligations		_		12	
Total current liabilities		23,305		61,609	
Convertible notes, net		127,811		126,392	
Other long-term liabilities		4,696		5,814	
Total liabilities	\$	155,812	\$	193,815	
Stockholders' deficit:					
Common stock		8		6	
Additional paid-in capital		743,626		722,782	
Accumulated deficit		(826,843)		(788,686)	
Treasury stock		(19,078)		(19,078)	
Total stockholders' deficit		(102,287)		(84,976)	
Total liabilities and stockholders' deficit	<u>\$</u>	53,525	\$	108,839	



#### FORWARD-LOOKING STATEMENTS

This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical fact included in this presentation, including statements concerning our plans, objectives, goals, strategies, future events, plans or intentions relating to product candidates, estimates of market size, the anticipated timing, design and conduct of our planned pre-clinical and clinical trials, the anticipated timing for pre-clinical and clinical data, the development of our product candidates, the potential clinical benefits of our product candidates, including efficacy and safety benefits, the potential benefits of strategic partnerships and licensing arrangements and our intent to enter into any strategic partnerships or licensing arrangements, the timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated product development efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this presentation, including competition from third parties with respect to our product candidates; risks related to the supply and manufacturing of and complexity of components in our devices; whether we will be able to develop our precision medicine products, and, if developed, that such product candidates will be authorized for marketing by regulatory authorities, or will be commercially

We cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. Forward-looking statements are not historical facts and reflect our current views with respect to future events. Given the significant uncertainties, you should evaluate all forward-looking statements made in this presentation in the context of these risks and uncertainties and not place undue reliance on these forward-looking statements as predictions of future events. All forward-looking statements in this presentation apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this presentation. We disclaim any intent to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Industry and Market Data: We obtained the industry, market, and competitive position data used throughout this presentation from our own internal estimates and research, as well as from industry and general publications, and research, surveys, and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of the industry and market, which we believe to be reasonable. In addition, while we believe the industry, market, and competitive position data included in this prospectus is reliable and based on reasonable assumptions, we have not independently verified any third-party information, and all such data involve risks and uncertainties and are subject to change based on various factors. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.



2 @ 2023 Biora Therapeutics, Inc. All rights reserved.

#### Our mission is to reimagine therapeutic delivery

Innovating smart capsule technologies to deliver the right dose to the right place, safely



# NAVIcap™

TARGETED ORAL DELIVERY

Treatment at the site of disease in the GI tract could improve outcomes for patients with inflammatory bowel disease





# BIO*jet*™

SYSTEMIC ORAL DELIVERY

Needle-free, oral delivery of large molecules designed to replace injection for better management of chronic diseases

© 2023 Biora Therapeutics, Inc. All rights reserved.

#### THERAPEUTIC PIPELINE


	PROGRAM	INDICATION	DESIGN/FEASIBILITY	PRECLINICAL	CLINICAL
SOL	<b>NaviCap</b> ™ Targeted Oral Delivery Platform				
TARGETED THERAPEUTICS	<b>BT-600</b> NaviCap + tofacitinib	UC			
TAI	<b>BT-001</b> NaviCap + adalimumab variant	UC			
	<b>BioJet™</b> Systemic Oral Delivery Platform				
TICS	<b>BT-200</b> BioJet + GLP-1 agonist	Diabetes			
THERAPEUTICS	<b>BT-002</b> BioJet + adalimumab variant	Autoimmune			
	Ionis Collaboration BioJet + antisense therapy	Undisclosed			
SYSTEMIC	Large Pharma 1 Collaboration BioJet + undisclosed drug	Undisclosed			
	Large Pharma 2 Collaboration BioJet + undisclosed drug	Undisclosed			



# NAVI*cap*™ TARGETED ORAL DELIVERY PLATFORM

#### ULCERATIVE COLITIS: THE TREATMENT GAP

#### Despite therapeutics targeting different pathways, few patients achieve long-term remission



#### **ABOUT ULCERATIVE COLITIS**

- Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis (UC)
- UC causes inflammation and damage to the large intestine
- About 1 million people in the U.S. are affected with UC, and ~40,000 cases are diagnosed each year3

- Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6(7):589-595.
   Hirten RP, Sands BE. New Therapeutics for Ulcerative Colitis. Annu Rev Med. 2021;72:199-213.
   Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr. Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. Clin Gastroenterol Hepatol. 2017;15(6):887-863.
- 6 © 2023 Biora Therapeutics, Inc. All rights reserved

#### UNMET NEED IN ULCERATIVE COLITIS

#### Targeted delivery could enable rapid induction and improve patient response


#### **THERAPEUTIC CHALLENGES**

- Difficulty of achieving sufficient drug levels at site of disease
- Systemic toxicity issues may limit daily dosage of UC drugs
- Combination therapy is limited by toxicity

#### **POTENTIAL SOLUTION**

Targeted delivery is designed to increase drug levels at the site of disease, which is correlated with improved outcomes<sup>1</sup>

Reduced systemic uptake is designed to reduce toxicity and adverse events





Development in partnership with:



- Verstockt B. Alsoud D. van Oostrom J. et al. Tofacitinib tissue exposure correlates with endoscopic outcome. Poster presented. Crohn's and Colitis Organisation (ECCO). February 18, 2022, virtual.

  van Oostrom J. Verstockt B. Harped J. et al. Pharmacokinetic staffication of cytokine profiles during anti-TNF induction treatme colitis. Poster presented at: 17th Congress of the European Crohn's and Colitis Organisation (ECCO). February 18, 2022, virtua
- © 2023 Biora Therapeutics, Inc. All rights reserved

#### RESEARCH DATA SUPPORTS TARGETED APPROACH

#### Tissue drug concentration correlates with endoscopic outcomes in UC

30 consecutive UC patients with active endoscopic disease initiated treatment with tofacitinib and prospectively monitored

#### **RESULTS**

- Tofacitinib tissue exposure at the end of induction was associated with endoscopic improvement by week 16 (p=0.04)
- In responders (n=14), median tofacitinib tissue exposure exceeded IC<sub>90</sub>


Research presented at ECCO 2022 and DDW 2022 in collaboration with:







# TOFACITINIB TISSUE EXPOSURE EXCEEDED IC<sub>90</sub> IN RESPONDERS



Verstockt B. Alsoud D. van Oostrom J. et al. Tofacitinib tissue exposure correlates with endoscopic outcome. Poster presented at: 17th Congress of the European Crohn's and Colitis Organisation (ECCO). February 18. 2022. virtua



© 2023 Biora Therapeutics. Inc. All rights reserved.

### NAVICAP™ TARGETED DRUG DELIVERY PLATFORM Needle-free, oral drug delivery to the colon



#### **ORAL ADMINISTRATION**

 Convenient oral capsule the size of a fish-oil pill

#### **AUTONOMOUS LOCATION**

Proprietary GITrac<sup>™</sup>
 autolocation technology for
 accurate drug delivery
 regardless of fasted or fed state<sup>1</sup>

#### TARGETED DRUG DELIVERY

 Method designed to coat the length of the colon with liquid formulation, minimizing systemic uptake




1. Lee SN, Razag G, Stork C, et al. Potential effects of food on a novel Drug Delivery System (DDS) to deliver therapeutic compound into the colon. Poster presented at: Crohn's & Colitis Congress, January 19-21, 2023, Denver, CO.

9 © 2023 Biora Therapeutics, Inc. All rights reserved.

### NAVICAP™ TARGETED DRUG DELIVERY PLATFORM Autonomous location and delivery to the colon









https://biora.wistia.com/medias/r65935rbqs

10 © 2023 Biora Therapeutics, Inc. All rights reserved.


#### **DEVICE FUNCTION STUDIES**

#### Demonstrated accurate localization and delivery to colon



#### **ACCURATE DELIVERY TO COLON IN CANINES**

Pharmacokinetic data from two marker drugs administered in canine model




- Successful delivery to colon via device
- · No early release of drug
- · No drug absorption in upper GI tract

Biora Therapeutics Internal data

© 2023 Biora Therapeutics, Inc. All rights reserved

#### ACCURATE LOCALIZATION AND DELIVERY TO HUMAN COLON

Clinical device validation for localization and delivery function using scintigraphic imaging in patients with active ulcerative colitis



· Achieved distribution across the entire colon



#### **DEVICE FUNCTION STUDIES**

#### Three successful studies demonstrating device function in humans



#### PM-601 Device Function Study in **Healthy Volunteers – Fasted State**

#### PM-611 Device Function Study in Healthy Volunteers - Fasted and Fed

#### PM-602 Device Function Study in **Patients with Active UC**

• 100% of devices accurately identified

of a liquid payload, and achieved

distribution across the entire colon

Device was well tolerated and

ulcerative colitis patients3


performed as intended in active

entry into the colon, triggered release

- 83% of devices accurately identified entry into the colon (10/12)1
- · Achieved distribution of payload across the entire colon1
- · No early deployment before colon detection1
- · 100% of analyzed devices successfully identified entry to the colon and activated H2 gas cells for delivery in all fasted/fed schedules  $(39/39)^2$
- · 97.4% of analyzed devices activated the payload release function (38/39)<sup>2</sup>
- No serious adverse events reported<sup>2</sup>

#### **DEVICE FUNCTION** IN ACTIVE UC PATIENTS

 $(7/7)^3$ 





#### **DEVICE FUNCTION IN HEALTHY VOLUNTEERS**







- 1. Lee SN, Sandefer E, Doll W, et al. A Scintigraphic Study to Evaluate the Safety, Tolerability, and Functionality of a Drug Delivery System (DDS) Device in Healthy Volunteers in Fasted State. Poster presented at: American College of Gastroenterology Annual Scientific Meeting, October 21-26, 2022, Charlotte, NC.

  2. Lee SN, Razga G, Stork C, et al. Potential effects of food on a novel Drug Delivery System (DDS) to deliver therapeutic compound into the colon. Poster presented at: Crohn's & Colitis Congress, January 19-21, 2023, Deniver, CO.

  3. Martin K, Lee SN, Stork C, et al. A Scintigraphic Study to Evaluate the Localization and Delivery Function of a Drug Delivery System (DDS) Device in Patients with Active Ulcerative Collitis (UC) in Fasted State. Poster presented at: American College of Gastroenterology Annual Scientific Meeting, October 21-26, 2022, Charlotte, NC.




# BT-600 (NAVICAP™ + TOFACITINIB) PRECLINICAL STUDY RESULTS Reduced systemic uptake, better PK effect and coverage




Non-GLP study; 7 days/QD in canine model compared BT-600 (tofacitinib 10mg liquid formulation delivered via device) vs. standard oral tablet (tofacitinib 10mg)

#### **RESULTS**

- Reduced drug levels in blood vs. standard oral tablet
- Tissue drug levels at average
   ~100X higher along the length of
   the colon vs. standard oral tablet
- Data suggest that a dose lower than the standard 10mg tofacitinib may provide increased tissue levels while reducing systemic exposure








Biora Therapeutics internal data

13 © 2023 Biora Therapeutics, Inc. All rights reserved

# BT-600 (NAVICAP™ + TOFACITINIB) Clinical Development Plan






#### PHASE 1: SINGLE AND MULTIPLE ASCENDING DOSE STUDIES



#### Evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of BT-600 in healthy volunteers



15 © 2023 Biora Therapeutics, Inc. All rights reserved





#### ULCERATIVE COLITIS: TREATMENT LANDSCAPE

### Potential for market-leading efficacy in tofacitinib creates sizeable opportunity



- · Global annual sales forecast for ulcerative colitis therapeutics:
  - \$7 billion in 2022<sup>1</sup>
- >10 FDA-approved drugs for UC







16 © 2023 Biora Therapeutics, Inc. All rights reserved



# BlOjet™ SYSTEMIC ORAL DELIVERY PLATFORM

#### **UNMET NEED**

### Needles are associated with poor disease management



of diabetics miss 4+ injections per week1



of patients fail to maintain diabetes treatment due to injection concerns when using an injectable GLP-1 agonist<sup>2</sup>



higher discontinuation rate for diabetes patients initiating treatment with an injectable GLP-1 agonist vs. those starting oral therapy<sup>2</sup>



Frost & Sullivan research commissioned by Rani Therapeutics Holdings, Inc. https://ir.ranitherapeutics.com/static-files/b1f080bf-a860-4136-87cb-d6f7c49c1502
 Spain CV, Wright JJ, Hahn RM, Wivel A, Martin AA. Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes. Clin Ther. 2016;38(7):1653-1664.e1. doi:10.1016/j.clinthera.2016.05.009





# BIOJET™ SYSTEMIC DRUG DELIVERY PLATFORM Needle-free, oral delivery to small intestine



#### **ORAL CAPSULE**

 Convenient oral capsule the size of a multivitamin for ease of swallowing

#### **PRECISE DELIVERY**

Enteric trigger for precise timing of drug delivery to the small intestine

#### **NEEDLE-FREE ADMINISTRATION**

 Liquid jet injection to the small intestine to maximize systemic uptake

#### **RESEARCH COLLABORATIONS**

- · IONIS
- Large Pharma 1
- Large Pharma 2
- 19 © 2023 Biora Therapeutics, Inc. All rights reserved



### BIOJET™ SYSTEMIC DRUG DELIVERY PLATFORM Liquid jet delivery to the small intestine









https://biora.wistia.com/medias/embr15eh3a

20 © 2023 Biora Therapeutics, Inc. All rights reserved.

#### BT-200 PRECLINICAL PERFORMANCE



#### Excellent systemic uptake for orally delivered large molecules demonstrated in animals


Preclinical studies in (1) swine model with endoscopically placed, autonomous device compared to IV administration of a variant of adalimumab (BT-001) and (2) canine model with autonomous device to evaluate device function and safety

#### **RESULTS**

Recently published data demonstrated:

- Average bioavailability of 22% (up to 55%) for BT-001 in swine where drug was detected in blood1
  - For comparison, commercially available oral large molecules achieve 1% or less
- bioavailability²
   In canines, ≥ 83% deployment accuracy and consistent deployment time post gastric emptying in the small intestine, with no early deployment<sup>1</sup>
- No issues observed with safety or tolerability of the device3





- 1. Les SN. Stork C. Smith J. et al. Development of a submucosal injection device for an oral biotherapeutic delivery system. Poster presented at: Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference, Q 2022, Palm Springs, CA
  2. Novo Nordisk A/S Rybelsus (oral semaglutide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda\_docs/label/2021/213051s006ibl.pdf, Revised January 2023. Accessed March 3, 2023.
  3. Biora Therapeutics internal data or an oral biotherapeutic delivery system. Poster presented at: Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference, October 18-19.



21 © 2023 Biora Therapeutics, Inc. All rights reserved

#### PRECLINICAL RESULTS

#### Achieved more than double our target bioavailability levels using next-generation device



Observed variability (CV) similar to subcutaneous injection for each drug

51.3%

variant of adalimumab (monoclonal antibody) bioavailability average1

37%

semaglutide (GLP-1 receptor agonist) bioavailability average<sup>1</sup>

#### COMPARISON

- 15% target bioavailability<sup>2</sup>
- 64% bioavailability via subcutaneous injection in humans for adalimumab3

#### COMPARISON

- 15% target bioavailability<sup>2</sup>
- 1% bioavailability in humans for commercially available oral semaglutide4

- Biora Therapeutics preclinical studies in porcine model with endoscopically placed and activated next-generation device to evaluate device function. Internal data, pending presentation of results at upcoming conference(s).
   Biovavailability target of 15% set by Biora Therapeutics and pharma collaborators for progression of systemic therapeutics platform.
   Abbvie, Inc. Humina (adalimmabl) plackage insert]. U.S. Food and Drug Administration website. https://www.access/data.fda.gov/drugsatfda\_docs/label/2021/125057s417bl.pdf. Revised February 2021. Accessed March 3, 2023.
   Novo Nordisk A/S. Rybelsus (oral semaglutide) [package insert]. U.S. Food and Drug Administration website. https://www.access/data.fda.gov/drugsatfda\_docs/label/2021/1213051s006ibl.pdf. Revised January 2023. Accessed March 3, 2023.





#### **DEVELOPMENT TIMELINE**


### Systemic Therapeutics Platform Milestones



H1 2022	H2 2022	H1 2023	H2 2023	MILESTONES/CATALYSTS
Research-Grade Device Function				Successfully confirmed viability of platform with research-grade device
	Next-Gen Device Development			Incorporating updated medical- grade components
		Preclinical Data Generation		Intent to replicate data from research-grade device with next-generation device
			pand Collaborations & tnerships	Progress existing collaborations and develop additional agreements



#### Our mission is to reimagine therapeutic delivery





TARGETED ORAL DELIVERY

- Completing tox study analysis
- Preparing to file IND and enter the clinic






# BIO*jet*™

SYSTEMIC ORAL DELIVERY

- Completing development of next-generation device
- Progressing pharma collaborations

24 © 2023 Biora Therapeutics, Inc. All rights reserved



#### TARGETED THERAPEUTICS PUBLICATIONS

#### bioratherapeutics.com/publications



- Development of targeted therapeutic antibodies for the treatment of inflammatory bowel disease: A proof of concept. Poster presented at DDW 2019.
- A comparison of systemic versus targeted anti-TNFα antibody in treatment of colitis induced by adoptive transfer of CD44-/CD62L+ T-cells into RAG2-/- mice recipients. Presented at DDW 2019.
- Targeted delivery of soluble tofacitinib citrate to the site of inflammation to improve efficacy and safety. Poster presented at DDW 2021.
- 4. Development of a novel drug delivery system for treatment of Ulcerative Colitis. Poster resented at DDW 2021.
- 5. Development of a Novel Drug Delivery System to Deliver Drugs Directly to the Colonic Mucosa, Resulting in Improved Efficacy and Reduced Systemic Exposure for the Treatment of Ulcerative Colitis. Crohn's & Colitis 360. 2021, 3, 1–5.
- Tofacitinib tissue exposure correlates with endoscopic outcome. Oral presentation at DDW 2022 and BWG. Poster presented at ECCO 2022.
- Pharmacokinetic stratification of cytokine profiles during anti-TNF induction treatment in moderate-to-severe UC. Poster presented at ECCO 2022 and DDW 2022.
- 8. Pilot study to assess pharmacokinetic and pharmacodynamic markers following enema-dosing with adalimumab in patients with active ulcerative colitis. Poster presented at ACG 2022.
- 9. A scintigraphic study to evaluate the safety, tolerability, and functionality of a Drug Delivery System (DDS) device in healthy volunteers in fasted state. Poster presented at ACG 2022.
- 10. A scintigraphic study to evaluate the localization and delivery function of a Drug Delivery System (DDS) device in patients with active ulcerative colitis (UC) in fasted state. Poster presented at ACG 2022.
- 11. Development of a novel Drug Delivery System (DDS) to deliver drugs directly to the colonic mucosa to improve efficacy and reduce systemic exposure for the treatment of ulcerative colitis (UC). Poster presented at Crohn's & Colitis Congress 2023.
- 12. Potential effects of food on a novel Drug Delivery System (DDS) to deliver therapeutic compound into the colon. Poster presented at Crohn's & Colitis Congress 2023.





#### BIOJET™ SYSTEMIC DRUG DELIVERY PLATFORM

#### bioratherapeutics.com/publications



- 1. Development of *ex-vivo* and *in-vivo* models to assess the performance of an oral biotherapeutic delivery system (OBDS) capsule. Poster presented at the *Controlled Release Society Annual Meeting*, July 13-14, 2022 and at the *American College of Gastroenterology Annual Scientific Meeting*, October 21-26, 2022.
- 2. Assessing the performance of an oral biotherapeutic delivery system (OBDS) using intra-duodenal endoscopy delivery in *Yucatan* minipigs. Poster presented at the *Controlled Release Society Annual Meeting*, July 13-14, 2022 and at the *American College of Gastroenterology Annual Scientific Meeting*, October 21-26, 2022.
- 3. Development of preclinical models to assess the performance of the oral biotherapeutic delivery system (OBDS) capsule. Poster presented at the *Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference*, October 18-19, 2022.



#### INTELLECTUAL PROPERTY PORTFOLIO

### Diverse patent portfolio with 68 distinct patent families<sup>1</sup>

### **DEVICES**36 patent families covering:

- Device designs, materials, components & manufacturing
- GI localization
- Devices for targeted delivery to GI tract
- Devices for targeted GI sampling systems
- Devices for jet delivery into GI tissue

- THERAPEUTICS
  26 patent families covering:
- Treatment via ingestible device
- GI delivery PK/PD profiles
- GI delivery dosing regimens
- GI delivery drug combinations
- Liquid drug formulations

### SAMPLING & DIAGNOSTICS 6 patent families covering:

- GI sample preservation
- GI analyte detection & quantification systems
- Complementary diagnostic markers



1. Approximately 165 issued patents and 137 pending applications in major countries and regions around the world

